APA (7th ed.) Citation

Weichenthal, M., Schadendorf, D., Bastholt, L., Gavrilova, I., Haanen, J., Mangana, J., . . . Ascierto, P. (2023). 1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study. Annals of Oncology, 34, S665. https://doi.org/10.1016/j.annonc.2023.09.2238

Chicago Style (17th ed.) Citation

Weichenthal, M., et al. "1104P Efficacy of Immune Checkpoint Inhibition in Metastatic or Non-resectable Melanoma After Failure of Adjuvant Anti-PD1 Treatment: A EUMelareg Real-world Evidence Study." Annals of Oncology 34 (2023): S665. https://doi.org/10.1016/j.annonc.2023.09.2238.

MLA (9th ed.) Citation

Weichenthal, M., et al. "1104P Efficacy of Immune Checkpoint Inhibition in Metastatic or Non-resectable Melanoma After Failure of Adjuvant Anti-PD1 Treatment: A EUMelareg Real-world Evidence Study." Annals of Oncology, vol. 34, 2023, p. S665, https://doi.org/10.1016/j.annonc.2023.09.2238.